...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

GATC Biotech to Sequence 100,000 Human Genomes by 2014

| Print |
Tuesday, 28 September 2010 11:45 (UTC + 2)

GATC_Biotech_logo2

PacBio RS to support studies on rare variant, and structural variations and methylation patterns

 

Konstanz, Germany, September 28, 2010 / b3c newswire / – Within the next four years GATC Biotech plans to analyse 100,000 human genomes in particular for the pharmaceutical and diagnostic industry as well as for academic research. This will be realised by applying Illumina’s HiSeq 2000 as well as GATC Biotech’s latest acquisition, the single molecule sequencing platform PacBio RS.

 

To achieve this goal, GATC Biotech expands its business portfolio by opening a business unit for human genome analysis. This new strategic unit is located in the company’s German headquarters and focuses on the sequencing and bioinformatic analysis of human samples of all sizes; from small enriched regions to entire genomes.

 

“By the end of 2010 we will have analysed more than 100 human genomes, an even higher number as announced in 2007,” comments Dr. Kerstin Stangier, Director Business Development and head of the new business unit. “Based on this experience and know-how, we can offer highest flexibility and quality as well as short delivery times. The new business unit includes a LIMS controlled production workflow with automated library preparation and an extensive bioinformatics pipeline which can be adapted to any project goal. Current collaborations, for example with the International Cancer Genome Consortium, have been very helpful for the development of this pipeline.”

 

GATC Biotech is Europe’s leading sequencing service provider. The company more than doubled its staff within the past three years and has currently close to 120 employees.

 

 

Contact

GATC Biotech AG
Dr. Kerstin Stangier

Director Business Development
Jakob-Stadler-Platz 7
D-78467 Konstanz
Tel.: +49(0)7531-816065
Fax: +49(0)7531-816081
e-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
http://www.gatc-biotech.com/